Konzentrationsbestimmung eines Antibiotikums (Cefotaxim) in der Vaginalhaut nach präoperativer intravenöser Gabe

Hägele, D; Frühwirth, O; Strehl, Egid; Berg, Douglas E.

doi:10.1055/s-2008-1037091

Geburtsh Frauenheilk

1983

DOI: 10.1055/s-2008-1037091

|View full text |Cite

Konzentrationsbestimmung eines Antibiotikums (Cefotaxim) in der Vaginalhaut nach präoperativer intravenöser Gabe

D Hägele¹,

O Frühwirth²,

Egid Strehl³

et al.

Abstract: In 11 patients in whom an antibiotic (Cefotaxim) had been applied preoperatively, the tissue concentration was determined in the vaginal mucosa where postoperative infections after gynaecological operations are most common. The tissue concentration is compared with the minimum inhibition concentration of the pathogens identified directly before the operation in the cervicovaginal flora. In the case of the aerobic pathogens--with the exception of Pseudomonas aeruginosa--the concentration is far in excess of the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1990

1997

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cefotaxime

Todd¹,

Brogden²

1990

Drugs

View full text Add to dashboard Cite

Cefotaxime was the first 'third generation' cephalosporin to be marketed and is administered intramuscularly or intravenously. Similar to other agents of this class, it has a broad spectrum of in vitro activity, particularly against Enterobacteriaceae, including beta-lactamase-producing strains. Cefotaxime forms a metabolite, desacetylcefotaxime, which is antibacterially effective against many bacteria per se and acts additively or synergistically with cefotaxime against many strains. Since the first review of cefotaxime in the Journal, further studies have confirmed its value in the treatment of various infections: complicated urinary tract infections, lower respiratory tract infections, bacteraemia, meningitis, uncomplicated gonorrhoea, infections of skin and soft tissue and of bone and joints, and obstetric and gynaecological infections. Cefotaxime is effective as an empirical treatment of suspected infection due to susceptible organisms in immunocompromised patients and is of proven efficacy in serious, life-threatening infections in general. Cefotaxime reduces the incidence of postsurgical infection but the role of third generation cephalosporins in prophylaxis remains to be determined. The indications for which cefotaxime and other 'third generation' cephalosporins would be considered the most appropriate therapy remain largely dependent upon such factors as varied as cost, local medical custom, decisions of regulatory agencies and geographical patterns of bacterial resistance. Cefotaxime nevertheless represents a valuable 'third generation' cephalosporin of great clinical value in certain infectious conditions, in particular those which are serious and life-threatening and where resistance to therapies is creating a clinical problem.

show abstract

Cefotaxime

Todd¹,

Brogden²

1990

Drugs

View full text Add to dashboard Cite

show abstract

Cefotaxime

Brogden¹,

Spencer²

1997

Drugs

View full text Add to dashboard Cite

Cefotaxime is well established as an effective and well tolerated antibacterial drug for 3 times daily parenteral treatment of a variety of moderate to severe infections in hospitalised patients. Its frequency of administration has recently been reassessed with a 12-hourly regimen. Comparative studies in hospitalised patients with nosocomial or community-acquired lower respiratory tract infections, demonstrate the similar clinical and bacteriological efficacy of twice daily cefotaxime 1 or 2 g and the same daily dose of ceftriaxone, usually administered once daily. Cefotaxime 2 g twice daily was also similar in efficacy to ceftriaxone 2 g once daily. Retrospective and post-marketing studies also reveal the similar efficacy of cefotaxime administered twice and 3 times daily, and pharmacoeconomic studies suggest that total direct costs of treatment with cefotaxime compared is similar to that with other third generation cephalosporins in currently used dosage regimens. When administered twice daily, cefotaxime is, thus, an effective antibacterial agent for the treatment of hospitalised patients outside the intensive care unit with a variety of mild to moderate non-CNS infections caused by susceptible organisms. When appropriately administered twice daily there is potential to lower the cost of antibacterial treatment without compromising efficacy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Konzentrationsbestimmung eines Antibiotikums (Cefotaxim) in der Vaginalhaut nach präoperativer intravenöser Gabe

Cited by 2 publications

References 0 publications

Cefotaxime

Cefotaxime

Cefotaxime

Contact Info

Product

Resources

About